RxDoctor Payments Data

Amelia Valdez, MD

Family Medicine · Vallejo, CANPI 1124053012

Payments from drug & device makers

$12,147in general payments, 2019–2025

Across 689 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Johnson & Johnson$1K
  • Amarin Pharma, Inc.$1K
  • Boehringer Ingelheim$928
  • AstraZeneca$870
  • plus $4K from 21 others

What the payments were for

  • Food & beverage$12,129100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,147 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$52,123
Medicare patients
101
Services billed
466

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin118$140,935
OzempicSemaglutide59$98,458
TrulicityDulaglutide36$58,493
EliquisApixaban28$37,272
RybelsusSemaglutide18$34,334
XareltoRivaroxaban14$21,499
Tresiba Flextouch U-200Insulin Degludec27$13,982
Soliqua 100-33Insulin Glargine/Lixisenatide14$9,382
Combivent RespimatIpratropium/Albuterol Sulfate15$9,226
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$7,149
Breo ElliptaFluticasone/Vilanterol11$4,986
Valsartan84$3,604
Atorvastatin Calcium212$3,360
Rosuvastatin Calcium136$3,316
Metformin Hcl203$1,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$928$150,161133 claims
Novo NordiskOzempic, Rybelsus$2,360$132,79277 claims
Lilly USA, LLCTrulicity$1,755$58,49336 claims
PfizerEliquis$540$37,27228 claims
Johnson & JohnsonXarelto$1,443$21,49914 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$167$9,38214 claims
GSKBreo Ellipta$677$4,98611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Vallejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →